1. Ueda Y, Ikegami T, Akamatsu N, Soyama A, Shinoda M, Goto R, Okajima H, Yoshizumi T, Taketomi A, Kitagawa Y, Eguchi S, Kokudo N, Uemoto S, Maehara Y.Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2017 Aug;52(8):986-991. doi: 10.1007/s00535-017-1310-9.
2. Yoshizumi T, Mori M. Portal flow modulation in living donor liver transplantation: review with a focus on splenectomy. Surg Today 2020 Jan;50(1):21-29. doi: 10.1007/s00595-019-01881-y.
3. Kosai-Fujimoto Y, Yoshizumi T, Tomiyama T, Morinaga A, Iseda N, Inokuchi S, et al. Living-Donor Liver Transplantation for Patients With Extrahepatic Malignancy: A Series of 14 Patients in a Single Institution. Transplant Proc. 2020 Mar 3. pii: S0041-1345(19)31056-5. doi: 10.1016/j.transproceed.2019.12.041.
4. Yonemura Y, Yoshizumi T, Inokuchi S, Kosai-Fujimoto Y, Harada N, Itoh S, et al. Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria. Ann Gastroenterol Surg. In press.
5. Toshima T, Yoshizumi T, Kosai-Fujimoto Y, Inokuchi S, Yoshiya S, Takeishi K, et al. Prognostic Impact of Osteopenia in Patients Who Underwent Living Donor Liver Transplantation for Hepatocellular Carcinoma. World J Surg. 2020 Jan;44(1):258-267. doi: 10.1007/s00268-019-05206-5
6. Harada N, Yoshizumi T, Uchiyama H, Ikegami T, Itoh S, Takeishi K, et al. Impact of middle hepatic artery reconstruction after living donor liver transplantation using the left lobe. Clin Transplant. 2020 Mar 9:e13850. doi: 10.1111/ctr.13850.
7. Yoshizumi T, Harada N, Mori M. Biliary Stricture: The Achilles Heel of Pediatric Living Donor Liver Transplantation. Transplantation. 2019 Sep;103(9):1758-1759. doi: 10.1097/TP.0000000000002573.
8. Masano Y, Yagi S, Miyachi Y, Okumura S, Kaido T, Haga H, Kobayashi E, Uemoto S. Auxiliary xenotransplantation as an in vivo bioreactor-Development of a transplantable liver graft from a tiny partial liver. Xenotransplantation. 2019;26(6):e12545.10.1111/xen.12545
9. Ogawa K, Kaido T, Okajima H, Fujimoto Y, Yoshizawa A, Yagi S, Hori T, Iida T, Takada Y, Uemoto S. Impact of pretreatments on outcomes after living donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2019;26(2):73-81.10.1002/jhbp.602
10. Ueda Y, Kobayashi T, Ikegami T, Miuma S, Mizuno S, Akamatsu N, Takaki A, Ishigami M, Takatsuki M, Sugawara Y, Maehara Y, Uemoto S, Seno H. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2019;54(7):660-6.10.1007/s00535-019-01561-1